PMID- 11235993
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20191025
IS  - 0262-0898 (Print)
IS  - 0262-0898 (Linking)
VI  - 18
IP  - 2
DP  - 2000
TI  - Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with 
      invasiveness of breast cancer cells in vitro.
PG  - 171-8
AB  - Several matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) 
      were studied in highly invasive (MDA-MB-231) and slightly invasive (MCF-7, T47D, 
      BT-20) breast cancer cell lines. Investigations were carried out at the protein 
      level and/or at the mRNA level, either in cells cultured as monolayers on 
      plastic, or in cells seeded on a thin layer of Matrigel basement membrane matrix. 
      Analysis of MMP expression by RT-PCR showed expression of MMP-1. MMP-3, and 
      MMP-13 in highly invasive MDA-MB-231 cells, but not in slightly invasive cell 
      lines. The extracellular secretion of MMP-1 and MMP-3 by MDA-MB 231 cells could 
      be also shown by ELISA. TIMP-1 and TIMP-2 mRNAs were found in all cell lines, 
      however, the extracellular secretion of both TIMPs was much higher in MDA-MB-231 
      cells than in the other cell lines. When the cells were cultured on Matrigel 
      matrix, MMP-9 expression was induced in MDA-MB-231 cells only, as assessed by 
      RT-PCR and zymography experiments. The invasive potential of MDA-MB-231 cells 
      evaluated in vitro through Matrigel was significantly inhibited by the MMP 
      inhibitor BB-2516, by 25% and 50% at the concentrations of 2 x 10(-6) M and 
      10(-5) M, respectively. In conclusion, our data show that highly invasive 
      MDA-MB-231 cells but not slightly invasive T47D, MCF-7 and BT-20 cells express 
      MMP-1, MMP-3, MMP-9 and MMP-13. MMP-9 which is specifically up-regulated by cell 
      contact to Matrigel, may play a key role in the invasiveness of MDA-MB-231 cells 
      through basement membranes.
FAU - Balduyck, M
AU  - Balduyck M
AD  - Laboratoire de Biochimie, H pital Claude Huriez, Lille, France.
FAU - Zerimech, F
AU  - Zerimech F
FAU - Gouyer, V
AU  - Gouyer V
FAU - Lemaire, R
AU  - Lemaire R
FAU - Hemon, B
AU  - Hemon B
FAU - Grard, G
AU  - Grard G
FAU - Thiebaut, C
AU  - Thiebaut C
FAU - Lemaire, V
AU  - Lemaire V
FAU - Dacquembronne, E
AU  - Dacquembronne E
FAU - Duhem, T
AU  - Duhem T
FAU - Lebrun, A
AU  - Lebrun A
FAU - Dejonghe, M J
AU  - Dejonghe MJ
FAU - Huet, G
AU  - Huet G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Clin Exp Metastasis
JT  - Clinical & experimental metastasis
JID - 8409970
RN  - 0 (DNA Primers)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxamic Acids)
RN  - 0 (Laminin)
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - 0 (Proteoglycans)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - 119978-18-6 (matrigel)
RN  - 9007-34-5 (Collagen)
RN  - D5EQV23TDS (marimastat)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Base Sequence
MH  - Basement Membrane/enzymology
MH  - Breast Neoplasms/*enzymology/pathology
MH  - Collagen
MH  - DNA Primers
MH  - Drug Combinations
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Hydroxamic Acids/pharmacology
MH  - Laminin
MH  - Matrix Metalloproteinase Inhibitors
MH  - Matrix Metalloproteinases/*metabolism
MH  - *Neoplasm Invasiveness
MH  - Proteoglycans
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tissue Inhibitor of Metalloproteinases/metabolism
MH  - Tumor Cells, Cultured
EDAT- 2001/03/10 10:00
MHDA- 2001/04/03 10:01
CRDT- 2001/03/10 10:00
PHST- 2001/03/10 10:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/03/10 10:00 [entrez]
AID - 10.1023/a:1006762425323 [doi]
PST - ppublish
SO  - Clin Exp Metastasis. 2000;18(2):171-8. doi: 10.1023/a:1006762425323.